切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2013, Vol. 07 ›› Issue (06) : 427 -432. doi: 10.3877/cma. j. issn.1674-0807.2013.06.007

论著

乳腺导管原位癌及其微浸润的临床病理研究
霍雷军1, 郜红艺1,(), 郭玉娟1, 黎剑君2, 张安秦2, 王颀2   
  1. 1.510010 广州,广东省妇幼保健院暨广州医学院附属广东省妇女儿童医院病理科
    2.510010 广州,广东省妇幼保健院暨广州医学院附属广东省妇女儿童医院乳腺病中心
  • 收稿日期:2013-04-27 出版日期:2013-12-01
  • 通信作者: 郜红艺

Clinicopathologic study on breast ductal carcinoma in situ and microinvasion

Lei-jun HUO1, Hong-yi GAO1,(), Yu-juan GUO1, Jian-jun LI1, An-qin ZHANG1, Qi WANG1   

  1. 1.Department of Pathology,Guangdong Women and Children Hospital,Guangzhou Medical College,Guangzhou 511442,China
  • Received:2013-04-27 Published:2013-12-01
  • Corresponding author: Hong-yi GAO
引用本文:

霍雷军, 郜红艺, 郭玉娟, 黎剑君, 张安秦, 王颀. 乳腺导管原位癌及其微浸润的临床病理研究[J/OL]. 中华乳腺病杂志(电子版), 2013, 07(06): 427-432.

Lei-jun HUO, Hong-yi GAO, Yu-juan GUO, Jian-jun LI, An-qin ZHANG, Qi WANG. Clinicopathologic study on breast ductal carcinoma in situ and microinvasion[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(06): 427-432.

目的

探讨乳腺导管原位癌(DCIS)患者微浸润(MI)与其他临床病理参数的关系。

方法

回顾性分析2006年10月至2012年10月本院收治的131 例乳腺DCIS 患者的临床资料,采用Spearman 相关性分析检验DCIS-MI、淋巴结转移与其病理分级之间是否具有相关性,采用Fisher 确切概率法分析DCIS-MI 是否影响其淋巴结转移,比较DCIS 手术方式、病理级别、微浸润、腋窝淋巴结清扫是否影响其复发。

结果

(1)在131 例DCIS 的病理分级中,低级别60 例(45.8%),中级别60 例(45.8%),高级别11 例(8.4%), 各组DCIS-MI 分别有12 例、31 例、8 例,与病理分级之间具有相关性(r=0.375,P=0.000)。(2)共计76 例行前哨淋巴结活组织检查,3 例转移;56 例行腋窝淋巴结清扫,5 例转移。 腋窝淋巴结转移与微浸润有关(P=0.015),与病理分级之间无相关性(r=0.154,P=0.107)。 (3)本组DCIS 患者随访3月至6年,1 例中风死亡,3 例局部复发,无乳腺癌死亡。 DCIS 复发与手术方式、病理分级、微浸润、腋窝淋巴结清扫均无关(P=0.359、1.000、1.000、0.260)。

结论

DCIS 病理分级高易发生DCIS-MI;DCIS-MI易发生腋窝淋巴结转移。

Objective To investigate the correlations of microinvasion (MI) with other clinicopathologic parameters in the patients with breast ductal carcinoma in situ (DCIS).Methods The clinical data of totally 131 patients with DCIS treated in our hospital from October 2006 to October 2012 were retrospectively analyzed.Spearman correlation analysis was applied to detect the correlation between DCIS-MI, lymph node metastasis and pathologic grades. Fisher’s exact test was used to detect the correlation between DCIS-MI and lymph node metastasis, and analyze the influence of operation methods, pathologic grades, DCIS-MI and axillary lymph node dissection on recurrence.Results (1) In 131 cases of DCIS, there were 60 cases in low grade of DCIS(45.8%),60 in intermediate grade (45.8%) and 11 in high grade (8.4%). The microinvasion was found in 12,31 and 8 cases in each pathologic grade respectively, which implied that DCIS-MI was correlated with pathologic grades (r=0.375, P=0.000). (2) Seventy-six patients received sentinel lymph node biopsy and lymph node metastasis was found in 3 cases;56 patients received axillary lymph node dissection and lymph node metastasis was found in 5 cases. The incidence of axillary lymph node metastasis was related with DCIS-MI(P=0.015), but not correlated with pathologic grades (r=0.154, P=0.107). (3) During the follow-up of 3-72 months,1 case died of apoplexy,3 cases experienced a local recurrence and none died of breast cancer.The recurrence of DCIS was not related with operation methods, pathologic grades, DCIS-MI and axillary lymph node dissection (P=0.359,1.000,1.000,0.260).Conclusion The patients with higher pathologic grades of DCIS have a higher risk of DCIS-MI; the patients with DCIS-MI have a higher risk of axillary lymph node metastasis.

图1 乳腺导管原位癌的病理分级及微浸润(HE ×200) a:低级别导管原位癌;b:中级别导管原位癌;c:高级别导管原位癌;d:微浸润(黑色箭头).
表1 微浸润与导管原位癌病理级别的相关性
表2 导管原位癌前哨淋巴结转移与病理级别的相关性
表3 导管原位癌腋窝淋巴结转移与病理级别的相关性
表4 导管原位癌-微浸润与前哨淋巴结转移的关系
表5 导管原位癌-微浸润与腋窝淋巴结转移的关系
表6 乳腺导管原位癌复发与手术方式、病理分级、微浸润、腋窝淋巴结清扫的关系
[1]
龚西騟,丁华野. 乳腺病理学[M]. 北京:人民卫生出版社,2009:241-258.
[2]
Tavassoli FA, Devilee P. WHO classification of tumours:pathology and genetics of tumours of the breast and female genital organs [M]. Lyon: IARC Press,2003:60-73.
[3]
牛昀.乳腺导管内癌的基础与临床研究:一个应倍加重视的领域[J/CD].中华乳腺病杂志:电子版,2008,2(6):626-633.
[4]
Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast[M]. Lyon: IARC Press,2012:95-98.
[5]
Altintas S, Lambein K, Huizing MT, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast:a clinicopathologic study[J]. Breast J,2009,15(2):120-132.
[6]
姜越, 马文锋, 李翔. 乳腺导管内癌:附123 例(125 侧)报告[J]. 中国普通外科杂志,2009,18(5):431-434.
[7]
刘冰天,高海东,张凯,等. 乳腺导管内癌伴微浸润和粉刺样坏死的临床病理研究[J]. 中国现代普通外科进展,2011,14(8):606-609.
[8]
俸瑞发,邵志敏,宫晓洁. 乳腺导管原位癌的诊断和治疗(附371 例报道) [J]. 肿瘤防治杂志, 2005, 12(8):62l-622.
[9]
Ellsworth RE,Ellsworth DL,Love B,et al.Correlation of levels and patterns of genomic instability with histological grading of DCIS[J].Ann Surg Oncol,2007,14(11):3070-3077.
[10]
Meijnen P,Peterse JL,Antonini N,et al.Immunohistochemical categorisation of ductal carcinoma in situ of the breast[J].Br J Cancer,2008,98(1):137-142.
[11]
Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy[J]. J Natl Cancer Inst,2003,95(22):1692-1702.
[12]
连臻强,张江宇,王颀,等. 乳腺导管内癌及其微浸润癌病理和生物学指标表达差异的临床意义[J/CD]. 中华乳腺病杂志:电子版,2011,5(4):419-425.
[13]
Sue GR, Lannin DR, Killelea B, et al. Predictors of microinvasion and its prognostic role in ductal carcinoma in situ[J]. Am J Surg,2013,206(4):478-481.
[14]
Ballehaninna UK, Chamberlain RS. Utility of intraoperative frozen section examination of sentinel lymph nodes in ductal carcinoma in situ of the breast[J]. Clin Breast Cancer,2013,13(5):350-358.
[15]
Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? [J]. World J Surg Oncol,2007,5(1):10.
[16]
孙晓, 王永胜, 周正波, 等. 乳腺导管内癌前哨淋巴结活检术的临床意义[J]. 中华内分泌外科杂志,2010,4(1):28-31.
[17]
Zavagno G, Belardinelli V, Marconato R, et al. Sentinel lymph node metastasis from mammary ductal carcinoma in situ with microinvasion[J]. Breast,2007,16(2):146-151.
[18]
Sakr R, Barranger E, Antoine M, et al. Ductal carcinoma in situ: value of sentinel lymph node biopsy[J]. J Surg Oncol,2006,94(5):426-430.
[19]
Intra M, Brito JAD, Soteldo J, et al. Sentinel lymph node biopsy in intraductal carcinoma of the breast with microinvasion[J]. Int J Cancer Res,2005,1(1):1-4.
[20]
Sakorafas GH, Tsiotou AG. Ductal carcinoma in situ (DCIS)of the breast: evolving perspectives [J]. Cancer Treat Rev,2000,26 (2):103-125.
[21]
Colina Ruizdelgado F, Pilas Pérez M, Lora Pablos D.Analysis of the breast cancer survival in a public hospital during the period 1999-2008[ J]. Rev Esp Salud Publica,2012,86(6):589-600.
[22]
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy, and lumpectomy plus irradiation for the treatment invasive breast cancer[J]. N Engl J Med, 2002, 347(16):1233-1241.
[23]
Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast[J]. J Clin Oncol,2006,24(7):1031-1036.
[24]
Lee DY,Lewis JL,Wexelman BA, et al. The consequence of undertreatment of patients treated with breast conserving therapy for ductal carcinoma in-situ [J]. Am J Surg, 2013,206(5):790-797.
[25]
Vicini FA, Shaitelman S, Wilkinson JB, et al. Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy[J]. Breast J, 2013,19(4):365-373.
[26]
Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast[J]. Am J Surg,2003,186 (4):337-343.
[27]
于泳, 方志沂, 刘君. 123 例乳腺导管内癌临床特点和远期疗效[J]. 天津医科大学学报,2003,9(2):180-182.
[28]
Okumura Y, Yamamoto Y, Zhang Z, et al. Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion[J]. BMC Cancer,2008,8(1):287.
[29]
Padmore RF, Fowble B, Hoffman J, et al. Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience[J]. Cancer,2000,88(6):1403-1409.
[30]
Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion[J]. Cancer,1998,82(12):2382-2390.
[31]
周雷,王岩,宋新,等. 乳腺导管内癌的临床病理特点与治疗[J].中华医学杂志,2005,85(43):3025-3038.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[8] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[9] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[10] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[11] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[12] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[13] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[14] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要